GO:0035666 TRIF-dependent toll-like receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035666 describes the TRIF-dependent (MyD88-independent) branch of Toll-like receptor signaling, which is engaged primarily by TLR3 and TLR4 to drive IRF3-dependent type I interferon and late NF-kB responses.
• The pathway is defined by the adaptor TRIF (TICAM1), which is recruited to activated TLR3 and TLR4 and nucleates a signaling complex containing TRAF3, TBK1, IKKepsilon and IRF3.
• TRIF-dependent signaling is a validated pharmacological target: small molecules such as isobavachalcone selectively suppress TRIF-dependent TLR signaling without affecting MyD88-dependent arms.
• Selective TRIF-dependent TLR4 agonists have been engineered to dissociate the TRIF branch from MyD88 signaling, enabling dissection of pathway-specific outputs.
• Membrane and lipid metabolism impinge on the pathway: CD14-dependent TLR4 trafficking and sphingomyelin synthase activity both modulate TRIF-dependent signaling.
• Mitochondrial reactive oxygen species are required for full TRIF-dependent TLR3 signaling in bronchial epithelial cells during viral infection.
Description
Toll-like receptors (TLRs) are germline-encoded pattern-recognition receptors that detect conserved microbial and danger-associated molecular patterns and initiate innate immune signaling. Downstream of TLR engagement, two principal adaptor routes exist: the MyD88-dependent pathway, which is shared by most TLRs and drives rapid NF-kB and MAPK activation, and the TRIF-dependent (MyD88-independent) pathway, which is engaged by TLR3 and TLR4 and is responsible for IRF3-mediated type I interferon production and delayed NF-kB activation. The Gene Ontology term GO:0035666, TRIF-dependent toll-like receptor signaling pathway, captures this second route as a discrete biological process. Because the TRIF branch is central to antiviral defense, to the late-phase inflammatory response to lipopolysaccharide (LPS), and to the pathogenesis of inflammatory and autoimmune conditions, it is a high-value target for mechanistic and pharmacological studies. This article summarizes the authoritative GO annotation, the molecular mechanism, the key genes and proteins involved, disease links, and the experimental and CRISPR-based methods used to interrogate the pathway.
TRIF-dependent toll-like receptor signaling pathway At A Glance
| GO ID | GO:0035666 |
|---|---|
| GO term | TRIF-dependent toll-like receptor signaling pathway |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Transduction of TLR3/TLR4 signals via the TRIF adaptor to activate IRF3 and type I interferon responses, plus delayed NF-kB activation |
| Proximal adaptor | TRIF (TICAM1) |
| Principal receptors | TLR3 and TLR4 |
| Key downstream kinases | TBK1 and IKKepsilon |
| Key transcription factors | IRF3 and NF-kB |
What Is GO:0035666?
GO:0035666, TRIF-dependent toll-like receptor signaling pathway, is the biological process in which ligand-activated Toll-like receptors, chiefly TLR3 and TLR4, transduce signals through the adaptor protein TRIF (TICAM1) rather than MyD88. In this branch, TRIF recruitment leads to activation of TBK1 and IKKepsilon, phosphorylation and nuclear translocation of IRF3, and production of type I interferons, together with a delayed NF-kB-dependent inflammatory response. The term is therefore defined by the use of TRIF as the proximal adaptor and by the downstream IRF3/interferon axis that distinguishes it from MyD88-dependent signaling.
Why Is TRIF-dependent toll-like receptor signaling pathway Important in Cell Biology?
The TRIF-dependent pathway is the principal route by which TLR3 and TLR4 elicit type I interferon and delayed inflammatory gene expression, making it a central node in antiviral immunity and in the inflammatory response to bacterial LPS. Its pharmacological tractability is demonstrated by compounds such as isobavachalcone that selectively suppress TRIF-dependent signaling, and by synthetic TLR4 agonists engineered to activate the TRIF branch selectively. Because the pathway intersects with membrane trafficking and lipid metabolism and with mitochondrial reactive oxygen species, it is also a point of convergence for cellular stress and metabolic regulation of innate immunity.
• Drives IRF3-dependent type I interferon production downstream of TLR3 and TLR4.
• Mediates the MyD88-independent, late-phase NF-kB response to LPS.
• Is a validated pharmacological target, as shown by selective TRIF inhibitors such as isobavachalcone.
• Can be selectively engaged by synthetic TLR4 agonists, enabling pathway-specific interrogation.
• Is modulated by CD14-dependent TLR4 trafficking and endosomal sorting.
• Is influenced by sphingomyelin synthase activity and membrane lipid composition.
• Requires mitochondrial reactive oxygen species for full activation in bronchial epithelial cells during viral infection.
• Contributes to trained immunity programs in macrophages, which are otherwise dominated by MyD88-dependent signaling.
• Provides a mechanistic link between innate immune sensing and interferon-driven inflammatory pathology.
• Offers a defined set of druggable nodes (TRIF, TBK1, IKKepsilon, IRF3) for therapeutic development.
What Happens During TRIF-dependent toll-like receptor signaling pathway?
Receptor activation and TRIF recruitment
In simple terms: When TLR3 or TLR4 detects its ligand, it changes shape and calls in the adaptor protein TRIF to start the signal.
TLR3 is activated by double-stranded RNA, whereas TLR4 is activated by LPS; both can recruit the adaptor TRIF (TICAM1) to their intracellular TIR domains. For TLR4, this recruitment occurs from endosomal compartments following CD14-dependent trafficking of the receptor, a step that is required for TRIF-dependent signaling. The TRIF-dependent route is thus spatially and temporally distinct from the plasma-membrane-proximal MyD88 route.
Assembly of the TRIF signalosome
In simple terms: TRIF acts as a scaffold that gathers other proteins into a signaling hub.
Once recruited, TRIF nucleates a signaling complex that includes TRAF3 and the kinases TBK1 and IKKepsilon, which are the principal effectors of IRF3 activation. This TRIF-dependent signalosome is the defining biochemical feature of GO:0035666 and distinguishes it from MyD88-dependent signaling, which instead uses IRAK kinases and TRAF6.
IRF3 phosphorylation and type I interferon induction
In simple terms: The kinases in the TRIF hub switch on IRF3, which then turns on interferon genes.
TBK1 and IKKepsilon phosphorylate IRF3, promoting its dimerization and nuclear translocation, where it drives transcription of type I interferon genes. This IRF3-interferon axis is the hallmark output of the TRIF-dependent pathway and is not elicited by MyD88-dependent signaling alone. In bronchial epithelial cells, mitochondrial reactive oxygen species are required for full TRIF-dependent TLR3 signaling against viral infection, linking redox biology to interferon induction.
Delayed NF-kB activation
In simple terms: The same TRIF hub also switches on NF-kB, but more slowly than the MyD88 route.
In addition to IRF3 activation, TRIF signaling leads to delayed NF-kB activation and pro-inflammatory gene expression. This late NF-kB phase contributes to the sustained inflammatory response to LPS and is sensitive to modulation of membrane lipid composition, including sphingomyelin synthase activity. The temporal separation of MyD88-dependent and TRIF-dependent NF-kB activation is a key experimental readout for distinguishing the two branches.
Pharmacological and genetic dissection of the pathway
In simple terms: Specific chemicals and engineered ligands let researchers turn the TRIF branch on or off without touching the MyD88 branch.
Isobavachalcone has been shown to suppress the TRIF-dependent signaling pathway of Toll-like receptors, providing a chemical tool to isolate this branch. Conversely, a synthetic TLR4 agonist has been described that selectively activates TRIF-dependent signaling, enabling pathway-specific activation. These tools complement genetic approaches and are widely used to attribute phenotypes specifically to GO:0035666.
Key Genes Involved in GO:0035666 TRIF-dependent toll-like receptor signaling pathway
The following genes and proteins constitute the core machinery and principal modulators of the TRIF-dependent toll-like receptor signaling pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR3 | Receptor that detects double-stranded RNA and recruits TRIF | Central entry point for TRIF-dependent antiviral signaling |
| TLR4 | Receptor for LPS that signals through both MyD88 and TRIF | Model receptor for dissecting TRIF versus MyD88 branches |
| TICAM1 (TRIF) | Proximal adaptor that defines the pathway | Defining component of GO:0035666; knockout abolishes the branch |
| TRAF3 | Scaffold in the TRIF signalosome | Required for IRF3 activation downstream of TRIF |
| TBK1 | Kinase that phosphorylates IRF3 | Key effector kinase; target for pathway inhibition |
| IKBKE (IKKepsilon) | Kinase that cooperates with TBK1 to activate IRF3 | Redundant/parallel effector of IRF3 phosphorylation |
| IRF3 | Transcription factor driving type I interferon genes | Functional readout of TRIF-dependent signaling |
| NFKB1 | Transcription factor mediating delayed inflammatory gene expression | Readout of the late NF-kB arm of the pathway |
| CD14 | Co-receptor controlling TLR4 trafficking to endosomes | Determines access of TLR4 to the TRIF branch |
| SGMS1 | Sphingomyelin synthase affecting membrane lipid environment | Modulates TRIF-dependent TLR4 signaling |
| SGMS2 | Sphingomyelin synthase affecting membrane lipid environment | Modulates TRIF-dependent TLR4 signaling |
| MYD88 | Adaptor for the parallel MyD88-dependent branch | Used as a comparator to isolate TRIF-specific effects |
| IFNB1 | Type I interferon gene induced downstream of IRF3 | Quantitative readout of pathway activation |
| CXCL10 | Interferon-inducible chemokine | Downstream marker of TRIF-dependent signaling |
| IL6 | Pro-inflammatory cytokine | Readout of delayed NF-kB activation |
| TNF | Pro-inflammatory cytokine | Readout of delayed NF-kB activation |
| TRAF6 | Signaling intermediate shared with MyD88 branch | Helps distinguish shared versus branch-specific nodes |
How Is TRIF-dependent toll-like receptor signaling pathway Regulated?
TRIF-dependent signaling is regulated at multiple levels. Receptor trafficking controls access to the pathway: CD14-dependent endosomal sorting of TLR4 is required for TRIF recruitment and downstream signaling. Membrane lipid composition also matters, as sphingomyelin synthase activity affects TRIF-dependent TLR4 signaling in LPS-stimulated cells. Redox regulation is another layer, with mitochondrial reactive oxygen species required for full TRIF-dependent TLR3 signaling in bronchial epithelial cells. Pharmacological regulation is exemplified by isobavachalcone, which selectively suppresses the TRIF branch, and by synthetic TLR4 agonists that selectively activate it. Finally, the pathway operates alongside MyD88-dependent signaling, which dominates certain outputs such as trained immunity in macrophages, so the balance between the two branches shapes the overall response.
TRIF-dependent toll-like receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TICAM1 (TRIF) | Impaired antiviral and LPS responses | TRIF knockout macrophage and epithelial cell lines |
| TLR3 | Susceptibility to viral respiratory infection | TLR3 knockout bronchial epithelial cells |
| TLR4 | LPS-driven inflammatory signaling | TLR4 knockout macrophages with CD14 trafficking readouts |
| SGMS1/SGMS2 | Membrane lipid modulation of inflammation | Sphingomyelin synthase knockout or overexpression cells |
| IRF3 | Type I interferon-dependent antiviral immunity | IRF3 knockout or point-mutant reporter cells |
Infectious and antiviral immunity
TRIF-dependent signaling is a principal route for type I interferon induction downstream of TLR3 and TLR4, making it central to antiviral defense. In bronchial epithelial cells, mitochondrial reactive oxygen species are required for TRIF-dependent TLR3 signaling against viral infection, implicating the pathway in respiratory antiviral responses.
Inflammatory and LPS-driven pathology
The delayed NF-kB arm of TRIF-dependent signaling contributes to sustained pro-inflammatory gene expression after LPS stimulation. Because CD14-dependent TLR4 trafficking and sphingomyelin synthase activity modulate this branch, dysregulation of membrane trafficking or lipid metabolism could amplify TRIF-driven inflammation.
Therapeutic targeting of the TRIF branch
Selective suppression of TRIF-dependent signaling by isobavachalcone demonstrates that this branch can be pharmacologically inhibited without blocking MyD88-dependent signaling. Conversely, synthetic TLR4 agonists that selectively activate TRIF-dependent signaling provide tools for vaccine adjuvant and immunotherapy development.
Trained immunity and innate immune memory
Trained immunity in macrophages is driven predominantly by MyD88-dependent signaling, providing a contrast that helps define the specific contribution of the TRIF branch to innate immune memory. This distinction is important when interpreting how TLR4 engagement shapes long-term innate immune responses.
From TRIF-dependent toll-like receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is TRIF required for IRF3 activation? | TICAM1 (TRIF) knockout cell line |
| Does a specific residue in TBK1 control IRF3 phosphorylation? | TBK1 point-mutation knock-in |
| Can pathway activation be monitored in live cells? | IRF3 or IFNB1 reporter knock-in |
| Does overexpression of TRIF amplify interferon output? | TRIF overexpression cell model |
| Does loss of CD14 alter TRIF-dependent signaling? | CD14 knockout with TLR4 trafficking assays |
| Does sphingomyelin synthase activity modulate the pathway? | SGMS1/SGMS2 knockout or overexpression |
How to Study the TRIF-dependent toll-like receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RT-qPCR | Expression of IFNB1, CXCL10, IL6, TNF | Pathway activation readout |
| RNA-seq | Global transcriptional response | Branch-specific gene signatures |
| Western blot | Phosphorylated IRF3 and NF-kB components | Effector activation |
| Co-immunoprecipitation | TRIF-TRAF3-TBK1 complex assembly | Signalosome formation |
| Confocal imaging | TLR4 endosomal trafficking | CD14-dependent pathway access |
| Lipid manipulation assays | Sphingomyelin synthase activity effects | Membrane regulation of signaling |
| ROS measurement | Mitochondrial reactive oxygen species | Redox requirement in epithelial cells |
| Selective inhibitors/agonists | TRIF-dependent versus MyD88-dependent output | Pathway-specific pharmacology |
Transcriptional readouts of pathway activation
Quantitative PCR and RNA-seq of IRF3 target genes such as IFNB1 and CXCL10, together with NF-kB targets such as IL6 and TNF, are standard readouts for TRIF-dependent signaling. Comparing TLR3- or TLR4-stimulated wild-type and TRIF-deficient cells isolates the branch-specific contribution.
Protein phosphorylation and complex analysis
Western blotting for phosphorylated IRF3 and co-immunoprecipitation of TRIF with TRAF3, TBK1 and IKKepsilon are used to monitor signalosome assembly and effector activation. These assays are complemented by pharmacological controls such as isobavachalcone to confirm TRIF dependence.
Trafficking and imaging approaches
Because CD14-dependent TLR4 trafficking controls access to the TRIF branch, imaging and biochemical fractionation of endosomal compartments are used to map receptor localization. Lipid-focused assays, including manipulation of sphingomyelin synthase activity, reveal how membrane composition shapes the pathway.
Redox and mitochondrial measurements
Mitochondrial reactive oxygen species can be measured with fluorescent probes and antioxidant interventions to test their requirement for TRIF-dependent TLR3 signaling in epithelial cells. Such experiments link redox state to interferon induction.
How CRISPR Can Be Used to Study GO:0035666 TRIF-dependent toll-like receptor signaling pathway
Knockout
CRISPR knockout of TICAM1 (TRIF), TLR3, TLR4, TBK1, IKBKE or IRF3 is used to establish requirement and epistasis within GO:0035666. Knockout of CD14 or SGMS1/SGMS2 tests the contribution of trafficking and lipid metabolism to the pathway.
Point Mutation
Point mutations can be introduced into kinase domains of TBK1 or IKBKE, or into IRF3 phosphorylation sites, to test which residues are required for interferon induction downstream of TRIF. Such models refine the mechanistic map of the pathway beyond simple loss-of-function.
Knock-in
Knock-in of fluorescent or epitope tags at endogenous TRIF, IRF3 or TBK1 loci enables live-cell tracking of signalosome assembly and nuclear translocation. Reporter knock-ins at IFNB1 or CXCL10 provide quantitative, pathway-specific transcriptional readouts.
Overexpression
Overexpression of TRIF, TBK1, IKKepsilon or constitutively active IRF3 is used to amplify the pathway and test sufficiency, often in combination with selective inhibitors such as isobavachalcone. Overexpression of sphingomyelin synthases complements lipid-focused studies of the pathway.
How EDITGENE Supports TRIF-dependent toll-like receptor signaling pathway Research
Researchers studying TRIF-dependent toll-like receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in IRF3 activation, interferon induction or the delayed NF-kB response, or whether it merely correlates with pathway activity. Establishing causality requires clean genetic models in which the gene of interest is removed, mutated, tagged or overexpressed in a defined cellular background, ideally with isogenic controls and validated pathway readouts.
Contact EDITGENE today to design your custom CRISPR model for TRIF-dependent toll-like receptor signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TRAF6 Knockout HEK293 Cell Line | EDJ-KQ107 | Human | 7189 | Details Get a Quote |
| MAP3K7 Knockout HEK293 Cell Line | EDJ-KQ142 | Human | 6885 | Details Get a Quote |
| IKBKB Knockout HEK293 Cell Line | EDJ-KQ566 | Human | 3551 | Details Get a Quote |
| TICAM1 Knockout HEK293 Cell Line | EDJ-KQ593 | Human | 148022 | Details Get a Quote |
| TRAF3 Knockout HEK293 Cell Line | EDJ-KQ602 | Human | 7187 | Details Get a Quote |
| IRF3 Knockout HEK293 Cell Line | EDJ-KQ960 | Human | 3661 | Details Get a Quote |
| TLR4 Knockout HEK293 Cell Line | EDJ-KQ1491 | Human | 7099 | Details Get a Quote |
| TLR6 Knockout HEK293 Cell Line | EDJ-KQ7010 | Human | 10333 | Details Get a Quote |
| CD300LF Knockout HEK293 Cell Line | EDJ-KQ10491 | Human | 146722 | Details Get a Quote |
| CD274 Knockout HEK293 Cell Line | EDC07777 | Human | 29126 | Details Get a Quote |
| TICAM2 Knockout HEK293 Cell Line | EDJ-KQ15731 | Human | 353376 | Details Get a Quote |
| TICAM1 Knockout HeLa Cell Line | EDJ-KQ18035 | Human | 148022 | Details Get a Quote |
| IKBKB Knockout A-549 Cell Line | EDJ-KQ18953 | Human | 3551 | Details Get a Quote |
| IKBKB Knockout HCT 116 Cell Line | EDJ-KQ18954 | Human | 3551 | Details Get a Quote |
| IKBKB Knockout HeLa Cell Line | EDJ-KQ18955 | Human | 3551 | Details Get a Quote |
Displaying Records 1 To 15 Of 57 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About TRIF-dependent toll-like receptor signaling pathway
What is GO:0035666 TRIF-dependent toll-like receptor signaling pathway?
It is the biological process in which TLR3 and TLR4 signal through the adaptor TRIF (TICAM1) to activate IRF3 and type I interferon responses, plus a delayed NF-kB response, as distinct from MyD88-dependent signaling.
What genes are involved in TRIF-dependent toll-like receptor signaling?
Core genes include TLR3, TLR4, TICAM1 (TRIF), TRAF3, TBK1, IKBKE, IRF3 and NFKB1, with modulators such as CD14 and SGMS1/SGMS2.
How is TRIF-dependent signaling different from MyD88-dependent signaling?
TRIF-dependent signaling uses TRIF as the proximal adaptor and drives IRF3-mediated type I interferon production, whereas MyD88-dependent signaling uses MyD88 and IRAK kinases and drives rapid NF-kB and MAPK activation.
Which Toll-like receptors use the TRIF-dependent pathway?
TLR3 signals exclusively through TRIF, while TLR4 can signal through both TRIF and MyD88.
What is the role of TBK1 in TRIF-dependent signaling?
TBK1, together with IKKepsilon, phosphorylates IRF3 to promote its dimerization and nuclear translocation, leading to type I interferon gene expression.
Can TRIF-dependent signaling be inhibited selectively?
Yes; isobavachalcone has been shown to suppress the TRIF-dependent signaling pathway of Toll-like receptors, providing a selective chemical tool.
Are there agonists that selectively activate TRIF-dependent signaling?
Yes; a synthetic TLR4 agonist has been described that selectively activates TRIF-dependent signaling.
How does CD14 affect TRIF-dependent TLR4 signaling?
CD14 controls TLR4 trafficking to endosomal compartments, which is required for TRIF recruitment and downstream signaling.
Do membrane lipids regulate TRIF-dependent signaling?
Yes; sphingomyelin synthase activity affects TRIF-dependent TLR4 signaling in LPS-stimulated cells.
How can I study TRIF-dependent signaling in the lab?
Common approaches include RT-qPCR and RNA-seq of IFNB1 and CXCL10, western blotting of phosphorylated IRF3, co-immunoprecipitation of the TRIF signalosome, and CRISPR knockout or knock-in models.
Conclusion
GO:0035666, TRIF-dependent toll-like receptor signaling pathway, defines the MyD88-independent route by which TLR3 and TLR4 activate IRF3 and type I interferon responses, alongside a delayed NF-kB arm. Its defining adaptor TRIF, its effector kinases TBK1 and IKKepsilon, and its transcription factor IRF3 form a compact, druggable module that is modulated by receptor trafficking, membrane lipids and mitochondrial redox state. Selective inhibitors and agonists continue to refine our ability to interrogate this branch specifically. For researchers, combining CRISPR-based genetic models with transcriptional and biochemical readouts remains the most rigorous way to establish causality within this pathway.
References
- 1. Ciesielska A et al.. 2021. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling.. Cell Mol Life Sci 78(4):1233-1261 PMID: 33057840
- 2. Shin S et al.. 2022. Isobavachalcone suppresses the TRIF-dependent signaling pathway of Toll-like receptors.. Arch Pharm (Weinheim) 355(3):e2100404 PMID: 34964142
- 3. Owen AM et al.. 2022. MyD88-dependent signaling drives toll-like receptor-induced trained immunity in macrophages.. Front Immunol 13:1044662 PMID: 36439136
- 4. Takeda K et al.. 2015. Toll-like receptors.. Curr Protoc Immunol 109:14.12.1-14.12.10 PMID: 25845562
- 5. Bowen WS et al.. 2012. Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.. Sci Signal 5(211):ra13 PMID: 22337809
- 6. Kawai T et al.. 2005. Toll-like receptor downstream signaling.. Arthritis Res Ther 7(1):12-9 PMID: 15642149
- 7. Prymas K et al.. 2020. Sphingomyelin synthase activity affects TRIF-dependent signaling of Toll-like receptor 4 in cells stimulated with lipopolysaccharide.. Biochim Biophys Acta Mol Cell Biol Lipids 1865(2):158549 PMID: 31678513
- 8. Chu GE et al.. 2023. Mitochondrial Reactive Oxygen Species in TRIF-Dependent Toll-like Receptor 3 Signaling in Bronchial Epithelial Cells against Viral Infection.. Int J Mol Sci 25(1) PMID: 38203397
